May 27, 2020: “AbbVie announced that it will present new safety and efficacy results for RINVOQ™ (upadacitinib) in adult patients with moderate to severe active rheumatoid arthritis, primary data of RINVOQ for investigational use in psoriatic arthritis, as well as additional data on HUMIRA® (adalimumab) in psoriatic arthritis at the European E-Congress of Rheumatology (EULAR) 2020, June 3-6.
A total of 25 abstracts will be presented across multiple rheumatic conditions, including rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.
“As a leader in immunology for over two decades, AbbVie is dedicated to developing innovative therapies for patients living with debilitating, chronic immune-mediated conditions,” said Marek Honczarenko MD, PhD, vice president, global immunology development, AbbVie.
“The new research from across our portfolio presented at EULAR underscores our commitment to improving the standard of care and highlights the potential for our therapies to make a meaningful difference in patients living with rheumatic diseases.”
AbbVie will for the first time present data from the SELECT-CHOICE clinical trial.
It is the sixth study in the SELECT rheumatoid arthritis clinical trial program, evaluating efficacy and safety of RINVOQ compared to abatacept in patients with moderate to severe active rheumatoid arthritis and prior inadequate response or intolerance to biologic DMARDs.
In addition, new long-term efficacy and safety data of up to 72 weeks from the SELECT-COMPARE study and up to 84 weeks from the SELECT-MONOTHERAPY study, along with three additional analyses evaluating the safety profile of RINVOQ, will be presented.
In addition to sharing new data from the robust Phase 3 SELECT rheumatoid arthritis clinical trial program, AbbVie will present investigational data evaluating RINVOQ in adult patients with active psoriatic arthritis from the SELECT-PsA 1 study in a late-breaker presentation andprimary data from the SELECT-PsA 2 study.
In SELECT-PsA 1, RINVOQ was compared to placebo and adalimumab in patients with an inadequate response to non-biologic DMARDs. In SELECT-PsA 2, RINVOQ was compared to placebo in patients with an inadequate response to biologic DMARDs.
RINVOQ is being investigated for the treatment of psoriatic arthritis and its efficacy and safety have not been established.
AbbVie Data at EULAR
RINVOQ Abstracts
Rheumatoid Arthritis
- Efficacy and Safety of Upadacitinib Versus Abatacept in Patients with Active Rheumatoid Arthritis and Prior Inadequate Response or Intolerance to Biologic Disease-Modifying Anti-Rheumatic Drugs (SELECT-CHOICE): A Double-Blind, Randomized Controlled Phase 3 Trial; SAT0151; Poster View Session; Saturday, June 6, 2020; 10:30 a.m. – 12:00 p.m. CEST
- Upadacitinib as Monotherapy in Patients with Rheumatoid Arthritis and Prior Inadequate Response to Methotrexate: Results at 84 Weeks from the SELECT-MONOTHERAPY Study; THU0213; Poster View Session; Thursday, June 4, 2020; 11:50 a.m. – 1:30 p.m. CEST
- Long-Term Safety and Effectiveness of Upadacitinib or Adalimumab in Patients with Rheumatoid Arthritis: Results at 72 weeks from the SELECT-COMPARE Study; THU0201; Poster View Session; Thursday, June 4, 2020; 11:50 a.m. – 1:30 p.m. CEST
- Upadacitinib Monotherapy in Methotrexate-Naïve Patients with Rheumatoid Arthritis: Results at 72 weeks from SELECT-EARLY; THU0217; Poster View Session; Thursday, June 4, 2020; 11:50 a.m. – 1:30 p.m. CEST
- Radiographic Outcomes in Patients with Rheumatoid Arthritis Receiving Upadacitinib as Monotherapy or in Combination with Methotrexate: Results at 2 years from the SELECT-COMPARE and SELECT-EARLY Studies; THU0211; Poster View Session; Thursday, June 4, 2020; 11:50 a.m. – 1:30 p.m. CEST
- Characterization of Serious Infections with Upadacitinib in Patients with Rheumatoid Arthritis; FRI0141; Poster View Session; Friday, June 5, 2020; 11:50 a.m. – 1:30 p.m. CEST
- Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-Naïve Patients with Early Active Rheumatoid Arthritis Receiving Treatment within 3 months of Diagnosis: A Post-Hoc Analysis of the SELECT-EARLY Study; SAT0145; Poster View Session; Saturday, June 6, 2020; 10:30 a.m. – 12:00 p.m. CEST
- Efficacy and Safety of Upadacitinib in Patients from China, Brazil and South Korea with Rheumatoid Arthritis who have had Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs; SAT0160; Poster View Session; Saturday, June 6, 2020; 10:30 a.m. – 12:00 p.m. CEST
- Proteomics Analysis Comparing the Mode of Action of Upadacitinib and Adalimumab Head to Head in Rheumatoid Arthritis Identifies Novel, Discrete Early Immune Pathway Modulation in the SELECT-COMPARE Phase 3 Study; FRI0026; Poster Tour Session; Friday, June 5, 2020; 11:50 a.m. – 1:30 p.m. CEST
- Sustainability of Response to Upadacitinib as Monotherapy or in Combination Among Patients with Rheumatoid Arthritis and Prior Inadequate Response to Conventional Synthetic DMARDs; THU0207; Poster View Session; Thursday, June 4, 2020; 11:50 a.m. – 1:30 p.m. CEST
- Incidence and Risk Factors for Herpes Zoster in Rheumatoid Arthritis Patients Receiving Upadacitinib; THU0218; Poster View Session; Thursday, June 4, 2020; 11:50 a.m. – 1:30 p.m. CEST
- Safety Profile of Upadacitinib Up to 3 Years of Exposure in Patients with Rheumatoid Arthritis; THU0197; Poster View Session; Thursday, June 4, 2020; 11:50 a.m. – 1:30 p.m. CEST
- Sustainability of Response Between Upadacitinib and Adalimumab Among Patients with Rheumatoid Arthritis and Prior Inadequate Response to Methotrexate; FRI0131; Poster View Session; Friday, June 5, 2020; 11:50 a.m. – 1:30 p.m. CEST
- Incidence and Risk of Venous Thromboembolic Events Among Patients With Rheumatoid Arthritis Enrolled in the Upadacitinib SELECT Clinical Trial Program; THU0195; Poster View Session; Thursday, June 4, 2020; 11:50 a.m. – 1:30 p.m. CEST
- Impact of Baseline Demographics and Disease Activity on Outcomes in Patients with Rheumatoid Arthritis Receiving Upadacitinib; FRI0140; Poster View Session; Friday, June 5, 2020; 11:50 a.m. – 1:30 p.m. CEST
- Upadacitinib Treatment and the Routine Assessment of Patient Index Data 3 (RAPID3) Among Patients with Rheumatoid Arthritis; THU0192; Poster View Session; Thursday, June 4, 2020; 11:50 a.m. – 1:30 p.m. CEST
- The Impact of Upadacitinib Versus Methotrexate or Adalimumab on Individual and Composite Disease Measures in Patients with Rheumatoid Arthritis; FRI0138; Poster View Session; Friday, June 5, 2020; 11:50 a.m. – 1:30 p.m. CEST
Psoriatic Arthritis and Axial Spondyloarthritis
- Efficacy and Safety of Upadacitinib Versus Placebo and Adalimumab in Patients with Active Psoriatic Arthritis and Inadequate Response to Non-Biologic Disease-Modifying Anti-Rheumatic Drugs (SELECT-PsA-1): a Double-Blind, Randomized Controlled Phase 3 Trial; LB-0001; Oral Abstract Presentation; Wednesday, June 3, 2020; 4:20 p.m. – 4:30 p.m. CEST
- Efficacy and Safety of Upadacitinib in Patients with Active Psoriatic Arthritis and Inadequate Response to Biologic Disease-Modifying Anti-Rheumatic Drugs (SELECT-PsA-2): a Double-Blind, Randomized Controlled Phase 3 Trial; OP0223; Oral Abstract Presentation; Friday, June 5, 2020; 10:15 a.m. – 10:25 a.m. CEST
- Improvements in Global Functioning and Health-related Quality of Life and Their Association with Disease Activity and Functional Improvement in Patients with Active Ankylosing Spondylitis Treated with Upadacitinib: Results from the SELECT-AXIS 1 Trial; THU0375; Poster Tour Session; Thursday, June 4, 2020; 11:50 a.m. – 1:30 p.m. CEST”
